 Connection
Aravindhan Veerapandiyan to Genetic Therapy
This is a "connection" page, showing publications Aravindhan Veerapandiyan has written about Genetic Therapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.502 |
|
|
|
-
Veerapandiyan A, Duvuru R. Transforming care for spinal muscular atrophy: A critical look at treatment paradigms. Mol Ther. 2024 Aug 07; 32(8):2435-2436.
Score: 0.894
-
Hamid OA, Hester DM, Matesanz SE, Wright S, Batley KY, Proud CM, Veerapandiyan A. Equitable Access of Delandistrogene Moxeparvovec for Patients With Duchenne Muscular Dystrophy: A Call for Discussion. Pediatr Neurol. 2024 Oct; 159:33-34.
Score: 0.224
-
Zaidman CM, Goedeker NL, Aqul AA, Butterfield RJ, Connolly AM, Crystal RG, Godwin KE, Hor KN, Mathews KD, Proud CM, Kula Smyth E, Veerapandiyan A, Watkins PB, Mendell JR. Management of Select Adverse Events Following Delandistrogene Moxeparvovec Gene Therapy for Patients With Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2024; 11(3):687-699.
Score: 0.215
-
Feldman AG, Parsons JA, Dutmer CM, Veerapandiyan A, Hafberg E, Maloney N, Mack CL. Subacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1. J Pediatr. 2020 10; 225:252-258.e1.
Score: 0.168
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|